Investor Relations

OPKO Submits Investigational New Drug Application to Initiate a Phase 2a Trial for its Long-Acting Coagulation Factor VIIa-CTP to Treat Hemophilia more »

OPKO and Pfizer Receive Regulatory Clearance for Global Agreement more »

OPKO Launches the 4Kscore Test in Mexico more »

OPKO Claros1 Analyzer Selected for Development of a Rapid Lyme Disease Test Under Immuno Technologies NIH Grant more »

Investor Relations

We are committed to serving the best interests of our shareholders. You will find key shareholder information and financial reports available to help put OPKO Health, Inc.'s financial performance into perspective.

  • Events


  • Stock Information


Ticker OPK Exchange NYSE
Last Price 12.13 Change 0.27 up
Open 11.89 Previous Close 11.86
Day High 12.32 Day Low 11.80
52-Week High 11.95 52-Week Low 7.32
Quotes delayed at least 20 minutes. Information provided by eSignal.